Temozolomide in the management of dopamine agonist–resistant prolactinomas
BC Whitelaw, D Dworakowska… - Clinical …, 2012 - Wiley Online Library
Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
Temozolomide in the management of dopamine agonist-resistant prolactinomas
BC Whitelaw, D Dworakowska, NW Thomas… - Clinical …, 2012 - kclpure.kcl.ac.uk
Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
[引用][C] Temozolomide in the management of dopamine agonist―resistant prolactinomas
BC WHITELAW, D DWORAKOWSKA… - Clinical …, 2012 - pascal-francis.inist.fr
Temozolomide in the management of dopamine agonist― resistant prolactinomas CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Temozolomide in the management of dopamine agonist-resistant prolactinomas
BC Whitelaw, D Dworakowska… - Clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
Temozolomide in the management of dopamine agonist–resistant prolactinomas
BC Whitelaw, D Dworakowska, NW Thomas… - Clinical …, 2012 - infona.pl
Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
BC Whitelaw, D Dworakowska, NW Thomas… - Clinical …, 2012 - europepmc.org
Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …